Psoriasis and Peroxisome Proliferator-Activated Receptor Pathway Regulation

According to a study published in Biochemical Genetics, daturataturin A (DTA) ameliorated lipid metabolism of psoriasis and exerted potential anti-psoriasis effects by regulating the peroxisome proliferator-activated receptor (PPAR) pathway in vitro.

Researchers established a psoriasis-like keratinocytes model by stimulating HaCaT cells with a cytokine cocktail (M5) comprising IL-17A, IL-22, oncostatin M, IL-1α, and tumor necrosis factor-α. Subsequently, DTA intervention was administered, and its effects and mechanisms on psoriasis were assessed in vitro.

Results indicated that DTA effectively inhibited hyperproliferation, promoted apoptosis, reduced the release of pro-inflammatory cytokines, downregulated keratin expression, and improved lipid metabolism. These effects were attributed to DTA's modulation of the PPAR signaling pathway in HaCaT cells stimulated by the M5 cocktail cytokines.

Overall, DTA demonstrated promising anti-psoriasis effects by ameliorating lipid metabolism and regulating the PPAR pathway in vitro. These findings suggest DTA's potential as a novel therapeutic agent for psoriasis treatment. The study sheds light on the intricate mechanisms underlying psoriasis pathology and highlights the therapeutic potential of DTA in addressing this challenging condition. Further research and clinical trials are warranted to validate these findings and explore DTA's efficacy and safety in clinical settings.

Reference
Wei Z, Zhong H, Yuan S, Chen C. Daturataturin A ameliorates psoriasis by regulating PPAR pathway. Biochem Genet. Published online February 20, 2024. doi:10.1007/s10528-024-10680-1